Literature DB >> 10516626

Response-selective C5a agonists: differential effects on neutropenia and hypotension in the rat.

A J Short1, N J Paczkowski, S M Vogen, S D Sanderson, S M Taylor.   

Abstract

Some in vivo activities of two complement C5a agonist analogues have been evaluated by measuring changes in blood pressure and neutropenia in the rat and comparing the results with their receptor affinities in peritoneal macrophages and polymorphonuclear leucocytes (PMNs). In vitro C5a receptor (C5aR) binding experiments showed that YSFKPMPLaR and YSFKD(NMeNle)PlaR had similar affinities for the macrophage C5aR (IC50 0.2, 0.1 microM respectively). In PMNs, the affinity of YSFKPMPLaR (IC50 0.1 microM) was similar to that in macrophages, whereas the affinity of YSFKD(NMeNle)PLaR for the PMN C5aR was >100 microM. Given i.v., YSFKD(NMeNle)PLaR had similar activity to YSFKPMPLaR on blood pressure but did not cause neutropenia. These results demonstrate selectivity of a new C5a agonist in vitro, which is paralleled in vivo. The results suggest the possibility of developing selective agonists of C5a for in vivo use in humans.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10516626      PMCID: PMC1571687          DOI: 10.1038/sj.bjp.0702847

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  19 in total

1.  Biologic activity of synthetic analogues of C5a anaphylatoxin.

Authors:  J A Ember; S D Sanderson; S M Taylor; M Kawahara; T E Hugli
Journal:  J Immunol       Date:  1992-05-15       Impact factor: 5.422

Review 2.  Role of complement, chemokines, and regulatory cytokines in acute lung injury.

Authors:  P A Ward
Journal:  Ann N Y Acad Sci       Date:  1996-10-31       Impact factor: 5.691

3.  Molecular adjuvant effects of a conformationally biased agonist of human C5a anaphylatoxin.

Authors:  R M Tempero; M A Hollingsworth; M D Burdick; A M Finch; S M Taylor; S M Vogen; E L Morgan; S D Sanderson
Journal:  J Immunol       Date:  1997-02-01       Impact factor: 5.422

4.  Anaphylatoxin C5a receptor mRNA is strongly expressed in Kupffer and stellate cells and weakly in sinusoidal endothelial cells but not in hepatocytes of normal rat liver.

Authors:  H L Schieferdecker; E Rothermel; A Timmermann; O Götze; K Jungermann
Journal:  FEBS Lett       Date:  1997-04-14       Impact factor: 4.124

5.  Decapeptide agonists of human C5a: the relationship between conformation and neutrophil response.

Authors:  S D Sanderson; L Kirnarsky; S A Sherman; S M Vogen; O Prakash; J A Ember; A M Finch; S M Taylor
Journal:  J Med Chem       Date:  1995-09-01       Impact factor: 7.446

6.  Expression of the receptor for complement C5a (CD88) is up-regulated on reactive astrocytes, microglia, and endothelial cells in the inflamed human central nervous system.

Authors:  P Gasque; S K Singhrao; J W Neal; O Götze; B P Morgan
Journal:  Am J Pathol       Date:  1997-01       Impact factor: 4.307

7.  Biologically active conformer of the effector region of human C5a and modulatory effects of N-terminal receptor binding determinants on activity.

Authors:  A M Finch; S M Vogen; S A Sherman; L Kirnarsky; S M Taylor; S D Sanderson
Journal:  J Med Chem       Date:  1997-03-14       Impact factor: 7.446

8.  S19 ribosomal protein cross-linked dimer causes monocyte-predominant infiltration by means of molecular mimicry to complement C5a.

Authors:  H Nishiura; Y Shibuya; T Yamamoto
Journal:  Lab Invest       Date:  1998-12       Impact factor: 5.662

9.  Human chemotaxis receptor genes cluster at 19q13.3-13.4. Characterization of the human C5a receptor gene.

Authors:  N P Gerard; L Bao; H Xiao-Ping; R L Eddy; T B Shows; C Gerard
Journal:  Biochemistry       Date:  1993-02-09       Impact factor: 3.162

10.  Reversibility of tachyphylaxis to C5A in guinea pig tissues, perfused human placental lobule, and umbilical artery.

Authors:  S M Taylor; A M Finch; A E Heron; L C Brown; T H Florin
Journal:  Inflammation       Date:  1994-12       Impact factor: 4.092

View more
  9 in total

1.  Third extracellular loop (EC3)-N terminus interaction is important for seven-transmembrane domain receptor function: implications for an activation microswitch region.

Authors:  Soumendra Rana; Thomas J Baranski
Journal:  J Biol Chem       Date:  2010-07-27       Impact factor: 5.157

2.  Enhancement of in vivo and in vitro immune functions by a conformationally biased, response-selective agonist of human C5a: implications for a novel adjuvant in vaccine design.

Authors:  Edward L Morgan; Brandon N Morgan; Elisabeth A Stein; Elizabeth L Vitrs; Marilyn L Thoman; Sam D Sanderson; Joy A Phillips
Journal:  Vaccine       Date:  2009-10-15       Impact factor: 3.641

3.  Single-step conjugation of bioactive peptides to proteins via a self-contained succinimidyl bis-arylhydrazone.

Authors:  Joy A Phillips; Edward L Morgan; Yuxiang Dong; Garry T Cole; Cody McMahan; Chiung-Yu Hung; Sam D Sanderson
Journal:  Bioconjug Chem       Date:  2009-09-29       Impact factor: 4.774

4.  Comparative protection against rat intestinal reperfusion injury by a new inhibitor of sPLA2, COX-1 and COX-2 selective inhibitors, and an LTC4 receptor antagonist.

Authors:  Thiruma V Arumugam; Naomi Arnold; Lavinia M Proctor; Michelle Newman; Robert C Reid; Karl A Hansford; David P Fairlie; Ian A Shiels; Stephen M Taylor
Journal:  Br J Pharmacol       Date:  2003-07-29       Impact factor: 8.739

5.  Comparative anti-inflammatory activities of antagonists to C3a and C5a receptors in a rat model of intestinal ischaemia/reperfusion injury.

Authors:  Lavinia M Proctor; Thiruma V Arumugam; Ian Shiels; Robert C Reid; David P Fairlie; Stephen M Taylor
Journal:  Br J Pharmacol       Date:  2004-05-24       Impact factor: 8.739

6.  Targeting macrophage activation for the prevention and treatment of Staphylococcus aureus biofilm infections.

Authors:  Mark L Hanke; Cortney E Heim; Amanda Angle; Sam D Sanderson; Tammy Kielian
Journal:  J Immunol       Date:  2013-01-30       Impact factor: 5.422

7.  Targeted Amino Acid Substitution Overcomes Scale-Up Challenges with the Human C5a-Derived Decapeptide Immunostimulant EP67.

Authors:  Abdulraman M Alshammari; D David Smith; Jake Parriott; Jason P Stewart; Stephen M Curran; Russell J McCulloh; Peter A Barry; Smita S Iyer; Nicholas Palermo; Joy A Phillips; Yuxiang Dong; Donald R Ronning; Jonathan L Vennerstrom; Sam D Sanderson; Joseph A Vetro
Journal:  ACS Infect Dis       Date:  2020-04-13       Impact factor: 5.084

8.  Model structures of inactive and peptide agonist bound C5aR: Insights into agonist binding, selectivity and activation.

Authors:  Soumendra Rana; Amita Rani Sahoo
Journal:  Biochem Biophys Rep       Date:  2015-03-24

9.  Pharmacological Stimulation of Phagocytosis Enhances Amyloid Plaque Clearance; Evidence from a Transgenic Mouse Model of ATTR Neuropathy.

Authors:  Eleni Fella; Kleitos Sokratous; Revekka Papacharalambous; Kyriacos Kyriacou; Joy Phillips; Sam Sanderson; Elena Panayiotou; Theodoros Kyriakides
Journal:  Front Mol Neurosci       Date:  2017-05-10       Impact factor: 5.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.